147 related articles for article (PubMed ID: 32044530)
1. Stereotactic ablative radiation therapy for pulmonary metastases: Improving overall survival and identifying subgroups at high risk of local failure.
Pasalic D; Lu Y; Betancourt-Cuellar SL; Taku N; Mesko SM; Bagley AF; Chance WW; Allen PK; Tang C; Antonoff MB; Balter PA; Mehran RJ; Welsh JW; Liao Z; Gomez D; Erasmus JJ; Nguyen QN
Radiother Oncol; 2020 Apr; 145():178-185. PubMed ID: 32044530
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic Ablative Radiation Therapy for Pulmonary Metastases: Histology, Dose, and Indication Matter.
Helou J; Thibault I; Poon I; Chiang A; Jain S; Soliman H; Erler D; Yeung L; Cheung P
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):419-427. PubMed ID: 28463162
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
[TBL] [Abstract][Full Text] [Related]
4. Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy.
Binkley MS; Trakul N; Jacobs LR; von Eyben R; Le QT; Maxim PG; Loo BW; Shultz DB; Diehn M
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1044-1052. PubMed ID: 26025776
[TBL] [Abstract][Full Text] [Related]
5. Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer.
Pasalic D; Betancourt-Cuellar SL; Taku N; Ludmir EB; Lu Y; Allen PK; Tang C; Antonoff MB; Fuller CD; Rosenthal DI; Morrison WH; Phan J; Garden AS; Welsh JW; Chang JY; Liao Z; Erasmus JJ; Nguyen QN
Head Neck; 2020 Aug; 42(8):1939-1953. PubMed ID: 32129548
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases.
Filippi AR; Badellino S; Guarneri A; Levis M; Botticella A; Mantovani C; Ragona R; Racca P; Buffoni L; Novello S; Ricardi U
Technol Cancer Res Treat; 2014 Feb; 13(1):37-45. PubMed ID: 23819496
[TBL] [Abstract][Full Text] [Related]
7. Improved local control following dose-escalated stereotactic ablative radiation therapy (SABR) for metastatic sarcomas: An international multi-institutional experience.
Singh R; Konrad A; Roubil JG; Jenkins J; Davis J; Austin Vargo J; Gogineni E; Sharma S
Radiother Oncol; 2024 Jan; 190():110020. PubMed ID: 38007042
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity.
Chance WW; Nguyen QN; Mehran R; Welsh JW; Gomez DR; Balter P; Komaki R; Liao Z; Chang JY
Pract Radiat Oncol; 2017; 7(3):e195-e203. PubMed ID: 27743801
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiation therapy for sarcoma pulmonary metastases.
Lebow ES; Lobaugh SM; Zhang Z; Dickson MA; Rosenbaum E; D'Angelo SP; Nacev BA; Shepherd AF; Shaverdian N; Wolden S; Wu AJ; Gelblum DY; Simone CB; Gomez DR; Alektiar K; Tap WD; Rimner A
Radiother Oncol; 2023 Oct; 187():109824. PubMed ID: 37532104
[TBL] [Abstract][Full Text] [Related]
10. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial.
Siva S; Bressel M; Mai T; Le H; Vinod S; de Silva H; Macdonald S; Skala M; Hardcastle N; Rezo A; Pryor D; Gill S; Higgs B; Wagenfuehr K; Montgomery R; Awad R; Chesson B; Eade T; Wong W; Sasso G; De Abreu Lourenco R; Kron T; Ball D; Neeson P;
JAMA Oncol; 2021 Oct; 7(10):1476-1485. PubMed ID: 34455431
[TBL] [Abstract][Full Text] [Related]
11. Long-term toxicity and survival outcomes after stereotactic ablative radiotherapy for patients with centrally located thoracic tumors.
Atalar B; Mustafayev TZ; Sio TT; Sahin B; Gungor G; Aydın G; Yapici B; Ozyar E
Radiol Oncol; 2020 Jun; 54(4):480-487. PubMed ID: 32589607
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
[TBL] [Abstract][Full Text] [Related]
15. Curative intent Stereotactic Ablative Radiation Therapy (SABR) for treatment of lung oligometastases from head and neck squamous cell carcinoma (HNSCC): a multi-institutional retrospective study.
Debbi K; Loganadane G; To NH; Kinj R; Husain ZA; Chapet S; Nguyen NP; Barillot I; Benezery K; Belkacemi Y; Calais G
Br J Radiol; 2022 May; 95(1133):20210033. PubMed ID: 35143326
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Single-fraction and Multi-fraction Stereotactic Radiotherapy for Patients with 18F-fluorodeoxyglucose Positron Emission Tomography-staged Pulmonary Oligometastases.
Siva S; Kirby K; Caine H; Pham D; Kron T; Te Marvelde L; Whalley D; Stevens MJ; Foroudi F; MacManus M; Ball D; Eade T
Clin Oncol (R Coll Radiol); 2015 Jun; 27(6):353-61. PubMed ID: 25698068
[TBL] [Abstract][Full Text] [Related]
18. Predictors of Respiratory Decline Following Stereotactic Ablative Radiotherapy to Multiple Lung Tumors.
Moding EJ; Liang R; Lartey FM; Maxim PG; Sung A; Diehn M; Loo BW; Gensheimer MF
Clin Lung Cancer; 2019 Nov; 20(6):461-468.e2. PubMed ID: 31377143
[TBL] [Abstract][Full Text] [Related]
19. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression.
Ho CB; Tsai JT; Chen CY; Shiah HS; Chen HY; Ting LL; Kuo CC; Lai IC; Lai HY; Chung CL; Lee KL; Tzeng HE; Lee KH; Lee HL; Chen SW; Chiou JF
Diagnostics (Basel); 2023 Apr; 13(9):. PubMed ID: 37174988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
